Psychedelic-assisted therapy (PAT) is moving from research settings towards broader implementation. During this transition, the therapist role is being formalised before the developmental pathways into the role are well understood. Existing clinicians are being selected, trained, and authorised to practise in a field marked by an emergent knowledge base and the convergence of multiple cultural...
Background Following Australia’s landmark 2023 decision to approve psilocybin and MDMA for clinical use, psychedelic-assisted therapy (PAT) is beginning to emerge within regulated mental health settings. This study investigates psychologists’ views on the relevance of psychedelic therapists’ lived-living experience (LLE) with psychedelics. While discussion around LLE is growing, little is known...